期刊文献+

盐酸埃克替尼治疗晚期肺腺癌的回顾性研究 被引量:7

A retrospective study of icotinib for the treatment of advanced non-small cell lung adenocarcinoma
下载PDF
导出
摘要 目的:探讨盐酸埃克替尼治疗晚期肺腺癌的有效性和安全性。方法:利用我院肿瘤患者数据库,回顾性筛选2012年1月–2014年1月于本中心接受盐酸埃克替尼治疗的晚期肺腺癌患者,对符合纳入标准的患者采集年龄、性别、PS评分、肿瘤分期、分子病理改变、用药情况、不良反应等相关临床资料,并对患者进行生存随访。结果:本研究共纳入42例患者,共27例患者接受了EGFR突变基因检测,其中EGFR突变阳性21例。近期疗效方面,RR为38.1%(16/42);DCR为73.8%(31/42)。中位随访时间为15个月,全组人群中位PFS为14.5个月(95%CI:12.4–16.6个月)。单因素分析显示PFS与年龄、PS评分、治疗前CEA水平、是否放疗、是否脑转移无关(P 〉0.05),而与性别、吸烟状况、EGFR基因突变状况有关。常见的不良反应为皮疹和恶心呕吐,大部分为Ⅰ~Ⅱ度。结论:盐酸埃克替尼治疗晚期肺腺癌临床效果显著,耐受性好,可作为EGFR敏感突变的新选择。 Objective: To evaluate the efficacy and safety of icotinib in patients with advanced non-small cell lung adenocarcinoma. Methods: A total of 42 patients with advanced non-small cell lung adenocarcinoma treated by icotinib from January 2012 to January 2014 in our hospital were collected. The information of the patients that met the included standards in respect of age, gender, PS score, tumor stage, pathological changes, medication, toxicities and so on were collected. Results:Among the 42 patients, 27 patients underwent EGFR mutation detection, and 21 cases were found EGFR mutation. The recent curative effect of RR was 38.1%(16/42) and DCR was 73.8%(31/42). The median follow-up time was iffteen months. The PFS of the whole group was 14.5 months (95%CI:12.4–16.6 months). The univariate analysis showed that FPS was more correlated with gender, smoking index, EGFR mutation, rather than age, PS score, CEA levels before treatment, whether radiotherapy and brain metastases or not (P 〉 0.05). The main toxicities of icotinib were rash, nausea and vomiting which do not need further treatment. Conclusion: The efficacy of icotinib for the treatment of advanced non-small cell lung adenocarcinoma is noble in longer PFS, with better disease control rates and less toxicity. Icotinib could be used as a new choice for the patients with EGFR mutation.
出处 《中国药物应用与监测》 CAS 2015年第2期69-72,共4页 Chinese Journal of Drug Application and Monitoring
基金 中国老年学学会课题(CGOS-03-2014-1-1-00500)
关键词 埃克替尼 肺腺癌 回顾性研究 Icotinib Lung adenocarcinoma Retrospective study
  • 相关文献

参考文献6

二级参考文献64

  • 1邬楠,王爱平,王印祥.表皮生长因子受体酪氨酸激酶抑制剂BPI-2009的抗肿瘤作用及其机制的研究[J].中国临床药理学与治疗学,2005,10(4):456-461. 被引量:7
  • 2张阳,张力,徐菲,王志强,赵洪云,管忠震,徐光川,潘振奎.吉非替尼记名供药计划(EAP)治疗晚期非小细胞肺癌患者的临床研究结果[J].癌症,2006,25(12):1561-1564. 被引量:9
  • 3GUAN ZM, CHEN XY, WANG YX, et al. Metabolite identification of new antitumor agent lcotinib in rats using liquid chromatograph/ tandem mass spectrometry [ J ]. Rapid Commun Mass Spectrom, 2008,22(14) :2176 -2184.
  • 4LIU DY, ZHANG L, JIANG J, et al. Phase Ⅰ studies of the novel oral EGFR inhibitor, lcotinib, in health male subjects [ C ]. 13^th World Conference on Lung Cancer(WCLC). San Francisco, 2009.
  • 5ZHANG L, JIANG J, LIU DY,et al. Icotinib, a potent and selective oral EGFR inhibitor, is well tolerated and active in patients with NSCLC :results from a phase Ⅰ/Ⅱ trial (13th World Conference on Lung Cancer(WCLC). San Francisco.
  • 6MOK TS, ZHOU C,WU YL,et al. Efficacy and safety of erlotinib in > 1200 East/South-East(E/SE) Asian patients(pts) with advanced non-small-cell lung cancer (NSCLC) [ J]. J Clin Oncol, 2008,26(Suppl) : S19001.
  • 7Shepherd FA,Rodrigues Pereira J,Ciuleanu T,Tan EH,Hirsh V,Thongprasert S,et al.Erlotinib in previously treated non-small-cell lung cancer.N Engl J Med 2005; 353:123-132.
  • 8Thatcher N,Chang A,Parikh P,Rodrigues Pereira J,Ciuleanu T,von Pawel J,et al.Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer:Results from a randomised,placebo-controlled,multicentre study (Iressa Survival Evaluation in Lung Cancer).Lancet 2005; 366:1527-1537.
  • 9Tan FL,Zhang L,Zhao Q,Liu DY,Hu YY,Liu Y,et al.Pharmacology and clinical evaluation of icotinib hydrochloride.Chin J New Drugs (Chin) 2009; 18:1691-1694.
  • 10Dunbar SA.Applications of LuminexR xMAP technology for rapid,high-throughput multiplexed nucleic acid detection.Clin Chim Acta 2006; 363:71-82.

共引文献186

同被引文献90

引证文献7

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部